The most common malignancies in childhood are leukaemias, brain tumours, lymphomas, neuroblastomas, soft tissue sarcomas and kidney tumours. At present, about 80% of childhood cancers can be treated successfully, which has significantly increased long-term survival. Concomitantly, adult gonadal function in childhood cancer survivors has become a concern. However, the immediate effect of cancer and its management on the reproductive axis function has received less attention. We conducted a review of the effects of malignancies and their treatments on the gonadal axis during childhood and adolescence. Some results are controversial, probably because the analyses do not distinguish between the malignancy types, their treatments and/or the age at treatment. However, there is agreement that cancer can partially affect gonadal function before treatment, as revealed by low circulating levels of inhibin B and anti-Müllerian hormone. Subsequently, chemotherapy transiently impairs the somatic component of the gonads (i.e. testicular Sertoli cells and ovarian granulosa cells) with normalization after treatment ends. The impact of chemotherapy may persist through adulthood after more intensive chemotherapy regimens, radiotherapy and conditioning for haematopoietic stem cell transplantation, when there is a severe impairment of the somatic component of the gonads or of the stem germ cells.

The development of effective therapies for the management of cancer in childhood has led to outstanding improvements in survival over the past decades. With this, a growing population of childhood cancer survivors are subject to long-term sequelae impacting on health. Endocrine disorders, and especially reproductive function in adulthood, have become an important concern. There is a large body of evidence on the long-term effects on adults of chemotherapy and radiotherapy given during childhood. In particular, the term ‘gonadotoxic’ treatments usually refer to the harmful effects of chemo/radiotherapy on the germ cell population of the gonads (i.e. those producing the oocytes and spermatozoa in the adult). However, little attention has been driven to the immediate effects of cancer and its treatment observed during childhood, especially their impact on the somatic cell populations of the gonads, which are the most numerous cell types before pubertal development. In this narrative review, we discuss the existing evidence on the immediate effects of cancer and its treatment on the function of the gonadal axis during childhood and adolescence.

Hypogonadism in the paediatric age group: Differences from hypogonadism in the adult

The most frequent concepts used to describe the physiology and nomenclature of the pathological conditions of the hypothalamic–pituitary–gonadal (HPG) axis derive from observations in the adult. Understanding the differences in the physiology of the HPG axis during postnatal development is essential for the interpretation of the clinical presentation of HPG disorders in children and adolescents.

Developmental physiology of the hypothalamic–pituitary–gonadal axis

Female developmental physiology

In the adult woman of reproductive age, follicle-stimulating hormone (FSH) regulates the function of granulosa cells of the follicle while luteinizing hormone (LH) acts on theca cells and the corpus luteum. Androgens are...
synthesized by the theca in response to LH and aromatized to oestrogens in the granulosa cells in response to FSH. Additionally, follicles produce inhibin B, whereas the corpus luteum produces inhibin A, which exerts negative feedback on pituitary FSH. Inhibin B production increases progressively as follicles grow from 4 to 12 mm. Conversely, anti-Müllerian hormone (AMH) is predominantly secreted by small follicles ≤2 mm, showing a progressive decrease in follicles 4–8 mm to reach very low production in follicles ≥10 mm. Serum AMH levels remain relatively stable during the menstrual cycle, reflecting the ovarian reserve and decline towards menopause.

The newborn shows very low levels of gonadotropins and ovarian hormones at birth, and a subsequent increase with one or two peaks during the first year of life. This active period of the female HPG axis declines after 1 year of age, when serum LH and oestrogens become undetectable, and serum FSH and inhibin B are detectable but low. AMH declines after 1 year of age, when serum LH and oestrogens become very low production in follicles ≥10 mm. Similarly to females, the newborn males show very low levels of gonadotropins and testicular hormones at birth, which increase with one or two peaks during the first year of life. However, high gonadotropin levels are in the same range as those observed in adults, the testes remain immature and sperm production does not occur, due to the lack of expression of the androgen receptor in Sertoli cells. Immature Sertoli cells have proliferating capacity in response to FSH until intratubular testosterone increases in puberty and provokes their maturation. The germ cell population is represented by spermatogonial stem cells, which can renew throughout life. Spermatogonia proliferate by mitosis during the active period of the HPG axis after birth but do not enter meiosis. During childhood, the rate of spermatogonial mitotic divisions decreases and it boosts again after pubertal onset. By then, spermatogonia can also enter meiosis to form spermatocytes, spermatids and spermatozoa. Defective function of Sertoli cells severely compromises germ cell survival and proliferation. Defective androgen production by Leydig cells results in lack of progression through meiosis but does not necessarily affect the survival of spermatogonia. Unlike the ovary, germ cell loss in the testis does not lead to seminiferous tubule or Leydig cell disappearance. Indeed, in the absence of germ cells, androgen production may be normal, and Sertoli cells can produce AMH normally. Nonetheless, inhibin B production is impaired as it needs both FSH and germ cell action on Sertoli cells.

**Hypogonadism in childhood and adolescence**

From this discussion, it follows that the concept of hypogonadism needs to be adapted when applying it to the paediatric population. Based upon developmental physiology, hypogonadism can be defined as an impaired gonadal function, based on the patient's age, which may result in a decreased secretion of sex steroids, AMH and/or inhibins, and/or a disrupted gamete production. Hypogonadism has different clinical presentations and health consequences depending on the age at which it is established, the gonadal cell population initially impaired and the level of the HPG axis primarily affected (Table 1).

**Male developmental physiology**

In the adult male, LH drives Leydig cell testosterone secretion, whereas FSH regulates Sertoli cell function and inhibin B production. Androgens and inhibin B exert negative feedback on LH and FSH secretion, respectively. A concerted action of androgens and FSH is necessary for normal sperm output.

Similarly to females, the newborn males show very low levels of gonadotropins and testicular hormones at birth, which increase progressively during the first month of life. However, high gonadotropin and androgen levels persist for only the first 3–6 months. Curiously, although these hormone levels are in the same range as those observed in adults, the testes remain immature and sperm production does not occur, due to the lack of expression of the androgen receptor in Sertoli cells. During the rest of infancy and childhood, most of the HPG axis becomes quiescent as in the female. Gonadotropin levels decline: LH is very low or undetectable, resulting in a complete disappearance of functional Leydig cells and androgen synthesis. Sertoli cells remain immature but active, and their function can be detected through the determination of AMH and inhibin B in serum.

With the onset of puberty, between 9 and 14 years of age, FSH initially boosts Sertoli cell proliferation, which provokes testicular enlargement beyond a volume of 4 mL. Within the testes, testosterone induces Sertoli cell maturation and adult spermatogenesis. Clinically, this is characterized by a decline in AMH and an increase in inhibin B, together with a progressive increase in testicular volume to 15–25 mL.

The dynamics of germ and somatic cell populations of the testis differ from that of the ovary. As mentioned, Leydig cells are present in the first 3–6 months of life, then they are no longer seen until the onset of puberty. Immature Sertoli cells have proliferating capacity in response to FSH until intratubular testosterone increases in puberty and provokes their maturation. The germ cell population is represented by spermatogonial stem cells, which can renew throughout life. Spermatogonia proliferate by mitosis during the active period of the HPG axis after birth but do not enter meiosis. During childhood, the rate of spermatogonial mitotic divisions decreases and it boosts again after pubertal onset. By then, spermatogonia can also enter meiosis to form spermatocytes, spermatids and spermatozoa. Defective function of Sertoli cells severely compromises germ cell survival and proliferation. Defective androgen production by Leydig cells results in lack of progression through meiosis but does not necessarily affect the survival of spermatogonia. Unlike the ovary, germ cell loss in the testis does not lead to seminiferous tubule or Leydig cell disappearance. Indeed, in the absence of germ cells, androgen production may be normal, and Sertoli cells can produce AMH normally. Nonetheless, inhibin B production is impaired as it needs both FSH and germ cell action on Sertoli cells.

**Female hypogonadism**

The activity of the HPG axis is clinically inappropriate in the female during foetal life and in childhood. Actually, girls with congenital primary hypogonadism (usually called primary ovarian insufficiency [POI] or failure [POF]) or with central hypogonadism are most usually diagnosed only at the age of puberty due to the absence of thelarche and menarche.
Review Paediatric Endocrinology

Table 1: Incidence of malignant tumours in paediatric patients

| Tumour type            | 0–14 years old | 15–19 years old |
|------------------------|----------------|-----------------|
|                        | WSR           | RI              | WSR          | RI              |
| Leukaemias             | 46.4          | 33.0%           | 41.8         | 22.7%           |
| Central NS             | 28.2          | 20.1%           | 39.5         | 21.4%           |
| Lymphomas              | 15.2          | 10.8%           | 28.5         | 15.4%           |
| Sym pathetic NS        | 10.4          | 7.4%            | 22.2         | 12.0%           |
| Soft tissue sarcomas   | 8.9           | 6.3%            | 19.9         | 10.8%           |
| Renal                  | 8.2           | 5.8%            | 14.4         | 7.8%            |
| Bone                   | 5.7           | 4.1%            | 12.9         | 7.0%            |
| Germ cell/Gonadal      | 4.9           | 3.5%            | 2.0          | 1.1%            |
| Epithelial/Melanoma    | 4.6           | 3.3%            | 1.4          | 0.8%            |
| Retinoblastoma         | 4.5           | 3.2%            | 1.2          | 0.7%            |
| Hepatic                | 2.3           | 1.6%            | 0.7          | 0.4%            |
| Other                  | 1.2           | 0.9%            | 0.0          | 0.0%            |
| TOTAL                  | 140.5         | 100%            | 184.5        | 100%            |

NS = nervous system; RI = relative incidence (tumour type/all tumours); WSR = age-standardized incidence rate (world standard population), cases per million children per year. Calculated from data obtained from Steliarova-Foucher et al.12

As discussed earlier, except for the transient activation period of the gonadal axis in the first year after birth, serum determination of oestradiol, progesterone and gonadotropins gives little or no information. Conversely, since small ovarian follicles secrete AMH and inhibin B, these biomarkers may be used throughout childhood to assess the status of the female gonads.42–44 Low levels indicate a decreased follicular pool and undetectable levels denote the absence of functional ovarian tissue. Noteworthy, the definitions of POI or POF coined for the adult woman, based on the finding of serum concentrations of FSH >25 or 40 IU/L twice at least 1 month apart, low sex steroid levels and amenorrhoea for at least 1 month, cannot be applied in paediatrics: occurrence of low sex steroids and no menstrual cycles reflects the physiological state in prepubertal girls and FSH remains below 25–40 IU/L during most of childhood in girls with primary hypogonadism.

Male hypogonadism

Unlike the observations in females, in males the function of the HPG axis during foetal and early postnatal life has a clinical impact. Because androgens are essential for testicular descent and penile growth during intrauterine development,46 and for persistent penile enlargement during the first 3–6 months of postnatal life,47 micropenis and cryptorchidism are suggestive of congenital hypogonadism in the male newborn.48 Conversely, hypogonadism acquired later in childhood may go clinically undiagnosed. Circulating sex steroid levels and gonadotrophin levels are not helpful, and only low serum levels of AMH49,50 or inhibin B51,52 may be indicative of gonadal function impairment.

Cancer in the paediatric age group

Epidemiology of cancer in children and adolescents

Each year, approximately 400,000 children and adolescents below the age of 19 years are diagnosed with cancer worldwide.53 The epidemiology of cancer in children and adolescents differs significantly from that observed in adults. Indeed, in the paediatric population, the most common types of cancers include leukaemias, brain tumours, lymphomas, neuroblastoma, soft tissue sarcomas and kidney cancer, especially Wilms tumours, with differences according to age and world regions. In high-income countries, cancer is the second leading cause of death in children, after accidents. The overall annual incidence of cancer is approximately 141 per million under the age of 14 years and 185 per million in adolescents aged 15–19 years. There is a slightly higher incidence rate in boys than in girls, with an overall incidence sex ratio of 1.14. However, sex-specific incidence varies according to cancer type, and renal, gonadal and epithelial tumours are more frequent in girls.

In children below the age of 14 years, leukaemias represent approximately 33% of all cancer types (Table 1).53 Tumours of the central nervous system follow in frequency with 20%, lymphomas account for ~11%, neuroblastomas represent 7%, soft tissue sarcomas and renal tumours ~6% each, bone tumours 4%, and germ cell/gonadal tumours, epithelial tumours/melanomas and retinoblastomas account for 3–4% each.

In adolescents aged 15–19 years (Table 1), lymphomas are the most common tumour type, with approximately 23% of all cancers, followed by epithelial tumours/melanomas (21%), leukaemias (15%), germ cell/gonadal tumours (12%), central nervous system tumours (11%), and bone and soft tissue sarcomas (between 7% and 8% each).53

Oncological treatments in children and adolescents

At present, ~80% of cancers occurring in children and adolescents can be diagnosed and successfully treated, although with differences amongst countries according to their economic capacity. A recent study comparing the global and regional burden of cancer in children 0–4 years old between 1990 and 2019 found that although the decrease in incident and prevalent cases was only 4.6% and 8.3%, respectively, the numbers of deaths and disability-adjusted life-years clearly declined by 47.8% and 47.7%, respectively.44 These advances in the management of childhood malignancies have significantly increased long-term survival and, concomitantly, the burden of long-term morbidity has raised concern. Approximately 40–50% of childhood cancer survivors develop an endocrine disorder in their lifetime.54 In particular, whether gonadal function is affected depends on risk factors including the sex and age of the patient, the diagnosis and its associated therapy.

Haematological malignancies

Haematological malignancies represent approximately 40% of cancers in the paediatric population,54-57 including acute lymphoblastic leukaemia.
Function of the Hypothalamic–Pituitary–Gonadal Axis in Children and Adolescents with Cancer

Figure 1: Risk stratification for patients with acute lymphoblastic leukaemia (ALL) according to the criteria set by the ALL IC-BFM 2002 trial.56,74

| Diagnosis          | Day 8                                      | Day 15                                      | Day 33                                      |
|--------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                    | Age 1–6 years and WBC <20,000 and blasts <1,000 | M1/M2                                      | M1/M2/M3                                    |
|                    | Age <1 or >6 years and WBC ≥20,000           | M1/M2                                      | M1/M2/M3                                    |
|                    | Blasts <1,000                               | M1                                        | M2/M3                                      |
| High risk          | t(9;22) or t(4;11)                          | M1/M2/M3                                    | High risk                                  |
|                    | or blasts ≥1,000                            |                                            |                                            |

ALL IC-BFM 2002: Acute Lymphoblastic Leukaemia Intercontinental Berlin–Frankfurt–Münster 2002. Standard risk: prednisone good response (<1×10⁹/L blasts in peripheral blood on day 8 after 7 days of prednisone and one dose of intrathecal methotrexate on day 1), age 1–6 years, initial WBC <20×10⁹/L, and M1 (<5% blasts) or M2 (5–25% blasts) marrow on day 15, and M1 marrow on day 33. Intermediate risk: prednisone good response, age <1 year or >6 years, and/or WBC ≥20×10⁹/L, and M1 or M2 marrow on day 15 and M1 marrow on day 33, or standard-risk criteria but M3 (>25% blasts) marrow on day 15 and M1 marrow on day 33. High risk: prednisone poor response (<1×10⁹/L blasts in peripheral blood on day 8 after 7 days of prednisone and one dose of intrathecal methotrexate on day 1), or intermediate risk and M3 marrow on day 15, or M2 or M3 marrow on day 33, or existence of chromosomal rearrangements t(9;22) (BCR-ABL) or t(4;11) (MLL-AF4). M1 = <5% bone marrow blasts; M2 = 5–25% bone marrow blasts; M3 = >25% bone marrow blasts; WBC = white blood cells.

Modified with permission from: Grinspon et al.59, copyright 2019 The Authors. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.

(ALL), acute myeloid leukaemia (AML) and non-Hodgkin lymphoma (NHL). Successful treatment currently occurs in 90% of cases, based on the use of intensive multi-drug, induction and consolidation regimens.12

In the case of ALL, risk stratification and treatment are usually assigned following the criteria set by the ALL IC-BFM 2002 trial (Risk-adjusted combination chemotherapy in treating young patients with acute lymphoblastic leukaemia; ClinicalTrials.gov Identifier: NCT00764907) (Figure 1). There are three risk groups: standard, intermediate and high risk. These are based on blast response to prednisone and intrathecal methotrexate, patient age, initial white blood cell count, percentage of blasts in bone marrow, and the presence of one of two chromosomal rearrangements: the t(9;22) translocation resulting in the fusion of the ABL proto-oncogene located on chromosome 9q34 with the break point cluster region (BCR) located on 22q11.2 and giving rise to the formation of the Philadelphia chromosome (BCR-ABL); or the t(4; 11) translocation where the mixed-lineage leukaemia (MLL) gene on chromosome 11q23 fuses with the AF4 gene in chromosome 4q21 producing a chimeric MLL/AF4 fusion transcript.

Standard- and intermediate-risk ALL and AML usually respond to less aggressive chemotherapy and do not require preconditioning chemotherapy for haematopoietic stem cell transplantation (HSCT) or HSCT conditioned with total body irradiation (TBI). Conversely, high-risk ALL and NHL may need HSCT with TBI or preconditioning chemotherapy including high cumulative doses of alkylating agents (e.g. busulphan, cyclophosphamide, melphalan or thiopeta).10 Patients with T cell ALL and high-risk patients aged 1 year or more usually receive 12 Gy prophylactic cranial radiotherapy, whereas children with initial involvement of the central nervous system receive therapeutic cranial radiotherapy with age adjustment: 12 Gy between 1 and 2 years old and 18 Gy for those older than 2 years.10 Gonadal irradiation is required only in cases of leukemic gonadal relapse.

Solid tumours

Brain tumours are treated with surgery and may need radiation therapy. The tumour itself or the surgical procedure may affect the hypothalamic–pituitary region. The radiation dose impairs endocrine function variably: growth hormone deficiency and precocious puberty can be seen with cranial radiotherapy doses ≥18 Gy, whereas other endocrine axis manifestations require doses ≥30 Gy.55 Tumours of the sympathetic nervous system are treated with spinal irradiation, which may affect the hypothalamic–pituitary region or the gonads, depending on the location of the tumour.

Soft tissue sarcomas stage I, renal (Wilms) and germ cell tumours may only require surgery. When no radiotherapy is required, the risk of endocrine compromise is low. Conversely, the risk increases in the cases of metastatic or high-risk sarcomas requiring high cumulative doses of alkylating agents (cyclophosphamide, ifosfamide) and testicular irradiation.40

Consequences of paediatric malignancies on hypothalamic–pituitary–gonadal axis function

The notorious advances made in the diagnosis and management of malignancies during childhood and adolescence has led to a growing population of cancer survivors who are susceptible to long-term sequelae impacting on health issues, especially endocrine disorders.1 Because cancer itself, as well as chemotherapy and radiotherapy, can affect gonadal function, loss of fertility and sex hormone deficiencies have become important concerns for childhood cancer survivors. We have conducted a review on the immediate effect of the occurrence of malignancies and of their treatment on gonadal function during childhood and adolescence.

Two main characteristics of the developmental biology of the HPG axis need to be considered when analysing the potential effects of childhood malignancies and their treatments on gonadal function. One is the different

September 1, 2021
mitotic activity of germ and somatic cells of the gonads between childhood and puberty. The other is the difference in the activities of the germ cells and the somatic cells between the ovary and the testis. All this may explain the differential effects of the diverse chemotherapies and radiotherapies on the HPG in childhood and adolescence. According to their mechanism of action, chemotherapy agents can be classified into ‘cell-cycle-specific’ and ‘non-cell-cycle-specific’ drugs (Table 2). Cell-cycle-specific agents inhibit mitosis by impairing DNA synthesis, thus affecting cells with a high proliferation rate. Germ cells involved in oogenesis and spermatogenesis during pubertal development are the most susceptible cell populations to cell-cycle-specific agents. Nonetheless, granulosa cells of small ovarian follicles and testicular spermatogonia and Sertoli cells also have a moderate proliferating activity in childhood. These cell types could also be affected by cell-cycle-specific drugs. The difference in their recovery is that the oocyte pool is fixed, with no stem cell renewal after birth, while granulosa cells, spermatogonia and Sertoli cells can renew if the gonads are not completely depleted of them by treatment. Another point to consider is that oocyte depletion results in granulosa cell exhaustion in the ovary, whereas spermatogonial depletion does not overtly affect Sertoli or Leydig cell numbers in the testis. On the other hand, non-cell-cycle-specific agents provoke direct DNA and RNA damage in both proliferating and cell-cycle-arrested cells, inducing apoptosis. Therefore, all gonadal cell types at any age would be susceptible to these agents.

### Girls

Initially, results from studies carried out with cohorts of adult survivors of childhood cancer drove the attention to the long-term deleterious effects of chemotherapy or radiotherapy on reproductive function. Results of cohorts treated decades ago may no longer be applicable at present given the changes in the diagnostic and therapeutic alternatives available. Furthermore, more recent observations have also highlighted the effect of the health status of children with malignancies at the moment of diagnosis on the function of the HPG axis. The published results from the largest cohorts of girls with childhood cancer focused on the function of the HPG axis are summarized in Table 3. Four studies assessed ovarian function from the time of diagnosis (i.e. pretreatment), until several months or years after treatment end, and those still of paediatric ages. One cross-sectional study focused on the ovarian status at the time of diagnosis, whereas two other studies evaluated the effect of cancer and its treatment only after the end of therapy.

Results may seem somewhat controversial regarding certain endpoints, and this could be due to the fact that some studies do not distinguish in their analyses the potential effects of the different underlying malignancies, their treatments and/or the age (prepubertal or pubertal) at which treatment was initiated and finished. However, most studies conclude that ovarian function is mildly impaired at the time of diagnosis, before any treatment is initiated. Brougham et al were the first to report in 22 girls (17 prepubertal, five pubertal) with solid malignancies requiring treatment with pulsed chemotherapy or radiotherapy that serum AMH was slightly but not significantly below that of the reference population mean. The analysis – which did not discriminate between tumour type or consider the duration of treatment (5–39 months) or the length of follow-up (4–43 months) – found that serum AMH was less affected in older girls, declined significantly during the initial six treatment cycles, and recovered to pre-treatment values in girls after >12 months of the end of treatment. Serum inhibin B was also below the mean at diagnosis and declined significantly in the first 4 cycles of oncological treatment. Although its circulating levels did not recover during follow-up, serum FSH did not increase. This could be due to the fact that most of the girls were still younger than 9 years. As already mentioned, it has been known for a long time that primary ovarian insufficiency can present with normal FSH in girls of prepubertal age.

The study by van Dorp et al. in 114 girls aged <18 years with haematological malignancies and 94 with solid tumours clearly showed that serum AMH is reduced at the time of diagnosis, in correlation with impairment of general health status in girls. The authors suggest that other factors, besides small follicle number, may influence ovarian AMH secretion.

In a small series of nine prepubertal girls with haematological and solid malignancies, Crofton et al. could not detect any impairment in ovarian function at diagnosis but showed a decline of serum inhibin B to undetectable levels during chemotherapy, with a variable degree of recovery 1–6 months after the end of treatment. In agreement with the study by Brougham et al., Crofton et al did not find any significant changes in gonadotropin levels.

In a more recent and larger study, van der Kooi et al. assessed at diagnosis 129 girls aged <18 years with cancer, of whom 49 were followed during and after treatment. The analysis did not distinguish

---

**Table 2: Chemotherapy drugs affecting gonadal function used in boys and adolescents**

| Relation to cell cycle | Mechanism of action | Drug class | Drug | Risk of prolonged infertility in adulthood |
|-----------------------|---------------------|------------|------|--------------------------------------------|
| Non-cell-cycle specific | Direct damage of nucleic acids (DNA and RNA) | Alkylating agents | Cyclophosphamide, procarbazine, melphalan, chlorambucil, BCNU, CCNU | High |
| | Induction of apoptosis | | | |
| | Induction of DNA strand breaks | Antitumour antibiotics | Bleomycin, actinomycin | Low |
| Cell-cycle specific | Inhibition of nucleic acid synthesis (DNA and RNA) | Antimetabolites | Methotrexate, mercaptopurine | Low |
| | Inhibition of cell proliferation (mitosis and meiosis) | Vinca alkaloids | Vincristine, vinblastine | Low |
| | Deamination of proteins | Podophyllotoxins | Asparaginase | Low |

BCNU = bischloroethyl nitrosourea; CCNU = chloroethyl cyclohexyl nitrosourea.
between haematological (n=31) and solid (n=18) malignancies. Serum levels of AMH were in the lowest part of the reference range in both premenarcheal and postmenarcheal girls at diagnosis. In premenarcheal girls undergoing standard-risk chemotherapy, no significant changes were seen in serum AMH during treatment and an increase was found during follow-up ≥12 months after treatment end. Conversely, serum AMH declined and did not recover to pretreatment levels in girls receiving high-risk chemotherapy. In postmenarcheal patients, serum AMH had already decreased significantly 1 month after treatment start and remained low after treatment end. The authors concluded that gonadotoxicity occurs more frequently in postmenarcheal girls and that premenarcheal girls are more likely to recover the function of the HPG axis. Therefore, they hypothesize that preventive treatment with gonadotropin hormone-releasing hormone analogues is useful to preserve ovarian function.

Table 3: Hypothalamic–pituitary–ovarian axis function in girls with cancer

| Study reference | Inclusion criteria | Exclusion criteria | Study design, treatment and follow-up | Main results |
|-----------------|-------------------|-------------------|--------------------------------------|--------------|
| Crofton et al. (2003)66 | Prepubertal girls, haematological or solid malignancies | Germ cell tumours | Longitudinal, chemotherapy, lumbar radiotherapy, analysis from diagnosis to 1–6 months after end of treatment | • Analysis not distinguishing between malignancy types (n=9)  
• Inhibit B: pretreatment normal, declined to undetectable during chemotherapy, variable recovery  
• FSH and LH: pretreatment normal, no significant changes during or after treatment |
| Curty et al. (2011)71 | Age <11 years, medulloblastoma or ependymoma | NA | Longitudinal, surgery, cranial irradiation, spinal irradiation, chemotherapy, analysis 75–166 months after end of treatment | • Analysis only after pubertal age, 13–16 years (n=22)  
• Early puberty requiring gonadotropin hormone-releasing hormone analogue treatment associated with radiotherapy (n=10)  
• Clinical progression of puberty normal in 15 girls: normal FSH and LH in 14 and high in 1, normal AMH and inhibit B in 11, low in 4  
• Abnormal progression of puberty in 7 girls: 2 with central hypogonadism (low FSH and LH), 4 with primary hypogonadism (low AMH and inhibit B, high FSH and LH), and 1 with combined (central and ovarian) hypogonadism (low AMH and inhibit B with inadequately normal FSH and LH) |
| Brougham et al. (2012)67 | Age <18 years, haematological or solid malignancies | ALL, brain tumours, gonadal tumours and primary gonadal dysgenesis | Longitudinal, chemotherapy, spinal or abdominal radiotherapy for 5–39 months, analysis 4–43 months after end of treatment | • Analysis not distinguishing between malignancy types in prepubertal (n=17) and pubertal (n=5)  
• AMH: pretreatment normal/low, positive correlation with age, declined during first 6 treatment cycles  
• Inhibit B: pretreatment normal/undetectable, declining during first 4 treatment cycles  
• FSH: pretreatment normal, no significant changes during treatment |
| Mörse et al. (2013)68 | Age <18 years, haematological or solid malignancies | Brain tumours, death shortly after diagnosis, ovarian cancer, contraceptives, Down syndrome | Longitudinal, chemotherapy, abdominal radiotherapy, HSCT, analysis at diagnosis and 0–36 months after end of treatment | • Analysis not distinguishing premenarche (n=23) and postmenarche (n=11), or between solid (n=23) and haematological (n=11) malignancies  
• AMH: pretreatment normal/low, positive correlation with age, declined during first 3 months of treatment, normalized in low-dose chemotherapy, undetectable in radiotherapy and HSCT  
• Inhibit B: pretreatment normal/undetectable, declined during first 3 months of treatment, normalized in low-dose chemotherapy, undetectable in radiotherapy and HSCT  
• FSH, LH and E2: pre-treatment normal, increase in FSH and LH, and variable changes in E2 at 3 months. No further changes thereafter |
| van Dorp et al. (2014)70 | Age <18 years, haematological or solid malignancies | Brain tumours, germ cell tumours | Cross-sectional study at diagnosis (no follow-up) | • 114 haematological malignancies, 94 solid tumours  
• AMH: pretreatment lower than in normal age-matched controls, associated with impaired general health status. No relation with age or malignancy type |
| Wedrychowicz et al. (2017)72 | Patients requiring HSCT for haematological or solid malignancies | Cross-sectional, HSCT (including TBI), abdominal radiotherapy, analysis 6–132 months after end of treatment | • 6 ALL, 4 neuroblastoma, 1 NHL, 1 HD. HSCT: 6 auto, 6 allo  
• AMH: undetectable or extremely low in all  
• Auto: 1 eugonadism (normal FSH, LH and inhibit B), 1 central hypogonadism (low FSH, LH and inhibit B), 2 primary hypogonadism (high FSH and LH, low/normal inhibit B), 2 combined hypogonadism (low inhibit B, inadequately normal FSH and LH) |
| van der Kooy et al. (2019)73 | Age <18 years, haematological or solid malignancies | NA | Longitudinal, chemotherapy, cranial, chest, abdominal radiotherapy, analysis from diagnosis to 10 months after end of treatment | • Analysis not distinguishing between haematological (n=31) and solid (n=18) malignancies  
• AMH: pretreatment normal/low in premenarche and postmenarche. No changes during treatment and increased after treatment in premenarche standard risk; declined with no recovery in premenarche high risk. Decreased after 1 month of treatment with no recovery after treatment in postmenarche |

ALL = acute lymphoblastic leukaemia; AMH = anti-Müllerian hormone; E2 = oestradiol; FSH = follicle-stimulating hormone; HD = Hodgkin disease; HSCT = haematopoietic stem cell transplantation; LH = luteinizing hormone; NA = data not available; NHL = non-Hodgkin lymphoma; TBI = total body irradiation.
Gonadal infiltration is one possibility to explain primary hypogonadism (ovarian dysfunction) before the start of treatment. The incidence of gonadal infiltration was high several decades ago. However, it is extremely infrequent nowadays, as revealed by an immunohistochemical assessment performed in a series of cryopreserved ovarian cortex samples obtained for fertility preservation before chemotherapy or radiotherapy from patients with leukaemia. Nevertheless, in approximately 75% of the cases, assessment of leukaemia genetic biomarkers in the ovarian tissue by polymerase chain reaction suggested the existence of leukaemic cells in the cryopreserved samples. Although their viability and malignancy is uncertain, the reimplantation of cryopreserved ovarian tissue cannot be recommended in patients with leukaemia.

High-risk treatments include those requiring HSCT. In a recent study, Wędrychowicz et al. assessed ovarian function in girls who underwent HSCT. The study included six girls 6–11 years old with ALL, who received allo-HSCT, and six girls 5 months to 13 years old with neuroblastoma, Hodgkin disease or NHL, treated with auto-HSCT. In all cases, the ovarian reserve was severely impaired, as reflected by extremely low or undetectable serum AMH between 6 months and 11 years after HSCT. However, the HPG axis still showed partially or completely preserved function in six cases.

In 22 patients with medulloblastoma or ependymoma aged <11 years, treated with surgical resection, cranial and/or spinal irradiation and chemotherapy, Cuny et al. found that 10 patients developed early puberty in association with low-dose cranial radiotherapy and required treatment with a gonadotropin hormone-releasing hormone analogue. After follow-up between approximately 6 and 14 years, clinical progression of puberty was normal in 15 girls; FSH and LH were in the reference range in 14 of them and high in 1, indicating an incipient primary ovarian failure. Serum AMH and inhibin B were normal in 11 cases and low in 4, reflecting a decreased ovarian reserve that did not yet have an overt impact on the HPG axis function. On the other hand, abnormal progression of puberty was seen in 7 girls: 2 with central hypogonadism, 4 with primary hypogonadism and 1 with combined (central and ovarian) hypogonadism.

In summary, cancer partially affects ovarian function, probably by impairing the general health status. In certain malignancies, such as leukaemias, ovarian infiltration – even submicroscopic – may also explain a decline in AMH and inhibin B production. The underlying pathogenic mechanisms need to be unveiled. In most cases, chemotherapy during childhood impairs ovarian function transiently, as revealed by a decline in AMH and inhibin B levels, with a normalization after treatment end. This might be explained by an effect of cell-cycle-specific chemotherapy agents mainly on proliferating granulosa cells of small follicles without inducing an increased germ cell apoptosis (i.e. not affecting the ovarian reserve). In pubertal girls, the impact of chemotherapy could be longer lasting, as oocytes have reinitiated meiotic divisions. At any age, more intensive chemotherapy regimens, abdomino-pelvic radiotherapy and HSCT usually result in a severe and persistent damage of the ovarian tissue. Cranial radiotherapy affects the hypothalamic–pituitary axis: doses 18–30 Gy induce early HPG axis activation resulting in precocious puberty, whereas doses >30 Gy provoke gonadotropin deficiency, resulting in delayed/absent/arrested puberty.

Boys

As in females, the first evidence of the deleterious effects of childhood cancer treatment on male reproductive function came from studies in cohorts of adult survivors. Here, also, the conclusions obtained from studies carried out decades ago may be outdated, owing to the progress made in diagnosis and treatment regimens. Results of the most recent studies of large cohorts of boys with cancer focused on the function of the HPG axis are summarized in Table 4. Two longitudinal studies assessed testicular function from the time of diagnosis, before any treatment, until several months or years after the end of treatment, whereas the other two longitudinal studies evaluated the effect of cancer therapy on testicular germ cells once therapy was initiated, during and after treatment. Two cross-sectional studies focused on testicular function at diagnosis. Finally, two studies analysed the effect of cancer and its treatment exclusively several months or years after treatment end, yet still in the paediatric age group.

In a series of 16 prepubertal boys with haematological and solid malignancies, Crofton et al. could not detect any impairment in testicular function at diagnosis, during or after treatment, except for one case who received an intensive chemotherapy regimen. However, much larger studies yielded somewhat different results. Krawczuk-Rybak et al. found that testicular volume and serum inhibin B were normal at diagnosis in 48 prepubertal boys – not distinguishing between those with haematological (n=34) and those with solid (n=14) malignancies – but decreased in 36 pubertal patients with either haematological (n=16) or solid (n=20) cancer with no impact on gonadotropins or testosterone. On the other hand, in a large cross-sectional study, Wigny et al. found normal inhibin B levels at diagnosis only in nine boys with nephroblastoma but a significantly lower mean inhibin B in serum in 215 boys with other solid tumours or haematological malignancies, not distinguishing between prepubertal and pubertal status. Moreover, the recent study by van der Kooi et al. found that serum inhibin B could be normal or low before treatment start in both prepubertal and pubertal boys with solid (n=19) or haematological (n=40) cancer and that it further decreased during the first month of therapy, with a partial recovery 10 months after the end of chemotherapy, which could be associated with cranial, chest and/or abdominal radiotherapy. Boys treated after pubertal onset seemed to be more affected than those treated at a prepubertal stage.

Analysing, retrospectively, boys and adolescents who received chemotherapy – with associated cranial radiotherapy in certain cases – for leukaemia several years earlier, Krawczuk-Rybak et al. found that testicular volume was not affected in prepubertal patients but was reduced in pubertal ones; mean serum inhibin B was significantly lower independently of pubertal status, while gonadotropins and testosterone were within the normal range. Somewhat different results were reported recently by Grinspon et al. in a large series of boys with leukaemia or NHL 1–12 years after the end of chemotherapy, associated with cranial radiotherapy or HSCT, in certain cases. While testis volume was normal in boys treated before puberty, it could be affected in those treated during puberty (Figure 2). These results suggest that the chemotherapy regimens used, including drugs of low risk for spermatogenic toxicity and doses of alkylating agents that are below the expected toxicity risk, do not significantly affect the Sertoli cell population, which accounts for the major proportion of testicular volume in childhood. Serum AMH and testosterone were within the normal range in all cases, while gonadotropins were normal in those treated before puberty and normal or slightly elevated in those who received treatment until after pubertal onset, especially in those who received high-risk therapy (Figure 3). Altogether, these observations indicate that the reduced testicular volume observed during puberty is due to the impairment of the germ cell population with no major damage of the somatic cell populations of the testis.
| Study reference                  | Inclusion criteria                                   | Exclusion criteria | Study design, treatment and follow-up                                                                 | Main results                                                                                                                                                                                                 |
|---------------------------------|------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Crofton et al. (2003)66         | Prepubertal boys, haematological and solid malignancies | Germ cell tumours  | Longitudinal, chemotherapy, lumbar radiotherapy, analysis from diagnosis to 1–6 months after end of treatment | • Analysis not distinguishing between malignancy types (n=16)  
• Inhibin B: pretreatment normal, no changes during chemotherapy, except for 1 case with intensive chemotherapy  
• FSH and LH: pretreatment normal, no significant changes during or after treatment |
| Krawczuk-Rybak et al. (2009)83   | Boys and adolescents, ALL                            | NA                 | Cross-sectional, chemotherapy, brain radiotherapy, analysis 1.9 ± 1.3 years (prepubertal) or 3.5 ± 5.3 years (pubertal) after end of treatment | • 27 prepubertal / 32 pubertal  
• Testis volume: normal in prepubertal, reduced in pubertal  
• Inhibin B: decreased in prepubertal and pubertal  
• Testosterone, FSH and LH: normal in prepubertal and pubertal |
| Nurmio et al. (2009)79          | Prepubertal boys, ALL                                | NA                 | Longitudinal, chemotherapy, analyses at end of induction therapy, end of chemotherapy and end of puberty | • Spermatogonia: number decreased 50% in standard-risk treatment (n=12) and 80% in high-risk treatment including cyclophosphamide (n=9). Without cyclophosphamide, no significant effect on spermatogonia. Leukaemia therapy, even without cyclophosphamide, delayed the initiation of spermatogenesis  
• Testicular volume, FSH, LH, testosterone and inhibin B at end of puberty: normal in standard-risk treatment. Variable compromise in high risk |
| Krawczuk-Rybak et al. (2012)81  | Boys and adolescents, haematological or solid malignancies | CNS or gonadal involvement | Cross-sectional study at diagnosis (no follow-up) | • Prepubertal (n=48) not distinguished between haematological (n=34) and solid (n=14). Pubertal (n=36), not distinguished between haematological (n=16) and solid (n=20)  
• Testis volume: pretreatment normal in prepubertal and early pubertal; decreased in mid-late pubertal  
• Inhibin B: pretreatment normal in prepubertal and early pubertal; decreased in mid-late pubertal  
• Testosterone, FSH and LH: pretreatment normal in prepubertal and pubertal |
| Wigny et al. (2016)32           | <18 years, haematological or solid malignancies      | Brain tumours, germ cell tumours | Cross-sectional study at diagnosis (no follow-up) | • Haematological (n=151), solid (n=73). Prepubertal (n=162), pubertal (n=82)  
• Inhibin B: pretreatment normal in nephroblastoma, normal/low in all other solid and haematological malignancies  
• Testosterone, FSH and LH: pretreatment normal in prepubertal and pubertal |
| Poganitsch-Korhonen et al. (2017)33 | Prepubertal boys, ALL undergoing testicular biopsy to examine possible testicular leukaemia at end of therapy | NA                 | Longitudinal, chemotherapy, CNS or tests radiotherapy, analyses at end of treatment and end of puberty | • Spermatogonia: number decreased in treatment with alkylating agents compared with non-alkylating. Total depletion of spermatogonia rare, more frequent in treatment with alkylating agents  
• End of puberty: no significant difference in testis volume, sperm count and incidence of azoosperma between alkylating and non-alkylating treatments |
| Grinspon et al. (2019)33        | Age 1–18 years, haematological malignancies          | CNS or gonadal involvement | Longitudinal, chemotherapy, cranial radiotherapy, HSCT, analysis 1–12 years after end of treatment | • Prepubertal, standard or intermediate risk (n=47) or high risk (n=4); pubertal, standard or intermediate risk (n=28) or high risk (n=4)  
• Testis volume: normal in prepubertal, normal or decreased in pubertal  
• AMH and testosterone: normal in all  
• FSH and LH: normal in prepubertal, normal or slightly elevated in pubertal |
| van der Kooi et al. (2019)32    | Age <18 years, solid or haematological malignancy    | NA                 | Longitudinal, chemotherapy, cranial, chest, abdominal radiotherapy, analysis 10 months after end of treatment | • Analysis not distinguishing between haematological (n=40) and solid (n=19) malignancies  
• Inhibin B: pretreatment normal/low in prepubertal and pubertal. Decreased after 1 month of treatment with partial recovery after treatment. Pubertal boys more affected than prepubertal |

ALL = acute lymphoblastic leukaemia; CNS = central nervous system; HSCT = haematopoietic stem cell transplantation; NA = data not available; NHL = non-Hodgkin lymphoma.
The two studies that focused on the germ cell population confirmed the already known toxicity of alkylating agents. Numrio et al. conducted a longitudinal study in boys with ALL. Compared with the end of induction therapy, the number of spermatogonia significantly decreased by the end of chemotherapy in boys who had received high-risk treatment including cyclophosphamide. Without cyclophosphamide, no significant effect on the number of spermatogonia was observed, but the initiation of spermatogenesis was delayed. In a more recent survey, including prepubertal boys with ALL treated with chemotherapy and cranial or testicular radiotherapy, Poganitsch-Korhonen et al. found that while the mean number of spermatogonia decreased in boys treated with alkylating agents compared with non-alkylating drugs, a complete depletion of spermatogonia is rare, thus allowing for a recovery of spermatogenesis during puberty in most cases.

In summary, Sertoli cell endocrine function of the testis may be affected by cancer during childhood and adolescence at the time of diagnosis, similarly to what is observed in ovarian endocrine function in girls. In boys, this is reflected by inhibin B levels in the low/normal range or clearly below reference levels. Chemotherapy acutely impairs Sertoli cell function, but it does not seem to affect Sertoli cell numbers, as can be deduced by the recovery of inhibin B or AMH levels in the follow-up at least 1 year after the end of treatment. Leydig cell function does not seem to be affected, as revealed by normal testosterone production during puberty. However, the slight increase in gonadotropins observed in some cases may be the reflection of a mild compromise of Sertoli and Leydig cell function. Non-cell-cycle-specific drugs, such as alkylating agents, transiently affect spermatogonial stem cell numbers, although they rarely produce a complete depletion. Consequently, azoospermia is not a frequent consequence of standard therapy for haematological malignancies. Intensive (high-risk) treatments including conditioning for HSCT and testicular radiotherapy are more deleterious, and pubertal status at the time of treatment is associated with a more severe effect on the HPG axis.

Conclusions

Compared with the extensive experience of the long-term effects of treatment on the reproductive axis in adult childhood cancer survivors, there are limited studies that have addressed the immediate effects of cancer itself and its treatment on gonadal function during childhood. In some cases, contradictory results may arise from studies not analysing separately the effects of malignancy types, treatments using drugs with different mechanisms of actions, or the pubertal status when treatment was administered. There is consensus that gonadal function may be partially affected at the time of diagnosis, before treatment is initiated, and that standard-risk chemotherapy has a transient deleterious effect on the somatic component of the gonads (i.e. Sertoli cells of the testis and granulosa cells of the ovary). The germ cell population is rarely completely depleted, which explains why gametogenesis is frequently present in young adult survivors. This raises the question of whether the concept of ‘gonadotoxic’ used for cancer treatments in adulthood should be applied identically in childhood.

Unfortunately, no established protocols exist for the assessment of the gonadal axis during the follow-up of children with cancer. Based on the concepts of the pathophysiology of hypogonadism in paediatric age groups discussed in this review and of the scarce published findings on the effects of cancer and its treatment on the gonadal axis during childhood, the clinical assessment that may be suggested for paediatric patients certainly differs from the well-established protocols used in adults. In boys, direct assessment of the germ cell population is not feasible, and the evaluation of the LH–Leydig cell axis would require stimulation tests that may not be informative. Therefore, measurement of direct serum markers of Sertoli cell function (i.e. inhibin B and AMH) seem to be the most sensible decision. Measurement of serum FSH, as an indirect marker of Sertoli cell dysfunction, may not be informative before pubertal onset. Similar concepts are applicable to the follow-up of prepubertal girls: serum AMH and inhibin B seem to be the most reliable markers of the function of the hypothalamic–pituitary–ovarian axis.
Function of the Hypothalamic–Pituitary–Gonadal Axis in Children and Adolescents with Cancer

[Diagram of Longitudinal follow-up of serum levels of anti-Müllerian hormone, testosterone and gonadotropins in 97 boys with acute lymphoblastic or myeloid leukaemia, or non-Hodgkin lymphoma]

In summary, further research is warranted to clarify the extent and duration of the specific effect of the different chemotherapy regimens on each gonadal compartment.

1. Crowne E, Gleeson H, Benghiat H, et al. Effect of cancer treatment on hypothalamic-pituitary function. Lancet Diabetes Endocrinol, 2015;3:568–76.
2. Jahnukainen K, Stukenborg JB. Clinical review: Present and future prospects of male fertility preservation for children and adolescents. J Clin Endocrinol Metab. 2012;97:4341–51.
3. Gebauer J, Higham C, Langer T, et al. Long-term endocrine and metabolic consequences of cancer treatment: A systematic review. Endocr Rev. 2019;40:711–67.
4. Kesari KK, Agnemall A, Henkel R. Radiations and male fertility. Reprod Biol Endocrinol. 2018;16:118.
5. Rey RA, Teno-Sempere M. Puberty: Recent advancements in its physiology and the management of its disorders. Curr Opin Endocrinol Metab Res. 2020;14:v–vii.
6. M Conti, R Chang. Folliculogenesis, Ovulation, and Luteogenesis. In: Jameson JL, De Groot LC, de Kretser D, Giudice LC, Grossman A, Melmed S, Potts JT, Jr., and Weir GC (eds). Endocrinology: Adult and Pediatric 7th Ed. Philadelphia: Elsevier Inc., 2016;2179–91.
7. De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. Lancet. 2010;376:911–21.
8. Andersen CY, Schmidt KT, Kristensen SG, et al. Concentrations of AMH and inhibin B in relation to follicular diameter in normal human small antral follicles. Hum Reprod. 2010;25:1282–7.
9. Long WQ, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 2000;85:540–4.
10. Rey R, Sabourin JC, Venara M, et al. Anti-Müllerian hormone is a
32. Rey RA, Grinspon RP, Gottlieb S, et al. Male hypogonadism: An analysis of anorxia in 26 boys. PLoS One. 2011;6:e23392.
33. Grinspon RP, Ropelato M, Bedecarras P, et al. Gonadotroph secretion pattern in anorchid boys: Pathophysiologic aspects and diagnostic usefulness. Clin Endocrinol (Oxf). 2016;85:599–607.
34. Grinspon RP, Guittonette S, Bedecarras P; Rey RA. Anti-Müllerian hormone and testicular function in prepubertal boys with cryptorchidism. Front Endocrinol (Lausanne). 2018;9:182.
35. Grinspon RP, Freire AV, Rey RA. Hypogonadism in pediatric health: Adult medicine concepts fall. Trends Endocrinol Metab. 2019;30:879–90.
36. Huhrender I, Hovatta O, La Marca A, et al. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol Metab. 2019;30:440–9.
37. Huhrender I, Hovatta O. The role of ovarian function in adult infertility. Best Pract Res Clin Endocrinol Metab. 2022;36:10194.
38. Fanum MF, Mendola BL. Genetics of ovarian insufficiency and deafness. Best Pract Res Clin Endocrinol Metab. 2022;36:10191.
39. van Iersel L, Mulder RL, Denzer C, et al. Hypothalamic-pituitary-gonadal axis in infants: Peak of inhibin B and testicular function. J Pediatr Endocrinol Metab. 2015;28:109–16.
40. Pastore LM, Christashion M, Stilling L, et al. Reproductive endocrinology and the alpha soup of diagnoses: DOR, POI, POF, FOR, and FOR. J Assist Reprod Genet. 2018;35:17–23.
41. Klotzior T, Fower PA, Hombach-Kronsch S. Molecular and genetic regulation of human pre- and early genital development. Dev Bio. 2004;270:1–8.
42. Buss M, Bosson D, Wiener KV. Postnatal penile length and growth rate correlate to serum testosterone levels: A longitudinal study of 1621 normal boys. Eur J Endocrinol. 2006;154:931–7.
43. Braslavsky D, Grinspon RP. Bulletin ML. Hypogonadotropic hypogonadism in infants with congenital hypoplasia: A challenge to diagnose at an early stage. J Pediatr Pract. 2015;8:299–97.
44. Grinspon RP, Dardenne P, Bedecarras P; Rey RA. Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in Turner’s syndrome. J Assist Reprod Genet. 2015;32:1027–30.
45. Weintraub A, Edlar-Goel A. Anti Müllerian hormone (AMH) determination in the pediatric and adolescent endocrine practice. Pediatr Endocrinol Rev. 2017;14:364–70.
46. Anderson SS. Clinical studies: Inhibit in the adult male. Min Clin North Am. 2007;90:61–7.
47. Anderson AM, Tepper LA, Heimsoth AM, et al. Longitudinal reproductive hormone profiles in infants. Peak of inhibin B levels in infant boys exceeds levels in adult men. J Clin Endocrinol Metab. 1998;83:675–81.
48. Bahr L, Reiter MA, Lippert LN, et al. Dynamic changes of reproductive hormone levels in normal and hypogonadal boys. J Pediatr. 2013;162:274–80.
49. Bahr L, Reiter MA, Lippert LN, et al. Dynamic changes of reproductive hormone levels in normal and hypogonadal boys. J Pediatr. 2013;162:274–80.
50. Bahr L, Reiter MA, Lippert LN, et al. Dynamic changes of reproductive hormone levels in normal and hypogonadal boys. J Pediatr. 2013;162:274–80.
51. Bahr L, Reiter MA, Lippert LN, et al. Dynamic changes of reproductive hormone levels in normal and hypogonadal boys. J Pediatr. 2013;162:274–80.
52. Condorelli RA, Cannarella R, Calogero AE, La Vignera S. Anti-Müllerian hormone and testicular function in children treated for hematologic malignancies as regards to chemotherapy treatments for haematologic malignancies. N Engl J Med. 2016;374:833–42.
53. Stary I, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL-S-80. J Clin Oncol. 2002;20:1274–84.
54. Grinspon RP, Anzirriana M, Prada S, et al. Safety of standardised treatments for haematologic malignancies as regards to testicular endocrine function in children and teenagers. J Pediatr Pract. 2015;31:248–9.
55. Ahluwalia K, Ernster I, Hou M, Schott S. Testicular function and fertility preservation in male cancer patients. Best Pract Res Clin Endocrinol Metab. 2015;29:267–92.
56. Stuková J, Vahlkus K, Huška M, Mitchell RT. Cancer treatment in childhood and testicular function: The importance of testicular volume as a marker of gonadal dysfunction. Cancer Treat Rev. 2016;39:649–57.
57. Mauri D, Gazzoli J, Zarkivskel G, et al. Chemotherapy associated ovarian failure. Front Endocrinol (Lausanne). 2020;11:372388.
58. van Terp E, van den Berg S, van den Berg S. Long-term endocrine sequelae after surgery, radiotherapy, and chemotherapy in children with mediastinal lymphomas. J Pediatr Hematol Oncol. 1997;19:915–22.
59. Pasqualini T, Eibschutz MD, Calvino AE, et al. Evaluation of gonadal function following long-term treatment for acute lymphoblastic leukemia in boys. J Pediatr Hematol Oncol. 2009;31:453–8.
60. Hène M, Ehinger M, Lindgren A, et al. Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatr Blood Cancer. 2013;60:1567–81.
61. van der Kooi AJ, van den Heuvel-Eibrink MM, van den Berg SAA, et al. Changes in anti-Müllerian hormone and inhibin B in children treated for cancer: A J Adolesc Young Adult Oncol. 2013;20:995–1003.
62. van Dorp W, van den Heuvel-Eibrink MM, den Vries AC, et al. Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer. J Pediatr. 2014;169:337–42.
63. Curry A, Thilin C, Brailly-Tabar S, et al. Inhibit B and anti-Müllerian hormone as markers of chemotherapy-induced gonadal toxicity. PLoS One. 2015;10:e0123163.
64. Reid H, Marsden HB. Gonadal infiltration in children with leukemia and lymphoma. J Pediatr. 1980;97:722–9.
65. Rosenkrands M, Andersson K, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Kliniker Tid. 2010;64:2186–90.
66. Feng L, Loo WY, Lui HY, et al. Melatonin prevents cyclophosphamide-induced primordial follicle loss by inhibiting ovarian tissue autophagy. Bone Marrow Transplant. 2015;50:1034–41.
67. Pasqualini T, Chemes H, Domené H, et al. Evaluation of anti-Müllerian hormone (AMH) as only possible marker in the assessment of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females reaching hormonal immaturity. J Pediatr Endocrinol Metab. 2015;28:880–90.
68. Mörse H, Elfving M, Lindgren A, et al. Acute onset of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females reaching hormonal immaturity. J Pediatr Endocrinol Metab. 2015;28:880–90.
69. Mörse H, Elfving M, Lindgren A, et al. Acute onset of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females reaching hormonal immaturity. J Pediatr Endocrinol Metab. 2015;28:880–90.